Terlipressin is a synthetic triglycyllysine derivative of vasopressin with vasoconstrictive, antihemorrhagic, and antidiuretic properties. Upon intravenous administration, terlipressin, an inactive prodrug, is biotransformed to its active moiety, lysine vasopressin (LVP), a nonselective vasopressin analogue with affinity for vasopressin receptors V1 (V1a), V2 and V3 (V1b). As a V1 agonist, terlipressin increases systemic vascular resistance, particularly in the splanchnic area, resulting in a decrease of portal pressure. V1 binding also promotes platelet aggregation and glycogenolysis, while V3 binding induces adrenocorticotropic hormone (ACTH) secretion. Compared to vasopressin, terlipressin has a minimal effect on V2 receptors, which are responsible for promotion of water reabsorption in the collecting ducts of the kidney via stimulation of cyclic AMP production.
CAT No: 10-101-342
CAS No: 14636-12-5
Synonyms/Alias: Terlipressin;14636-12-5;glypressin;Terlipressin acetate;glycylpressin;Terlipressine;Terlipressina;Terlipressinum;Lucassin;Terlipressine [INN-French];Terlipressinum [INN-Latin];Terlipressina [INN-Spanish];N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin;Terlipresina;Variquel;EINECS 238-680-8;UNII-7Z5X49W53P;DTXSID7048952;(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide;DTXCID0028878;7Z5X49W53P;Terlivaz;NCGC00185754-01;Terlipressine (INN-French);Terlipressinum (INN-Latin);Terlipressina (INN-Spanish);glycyl-glycyl-glycyl-L-cysteinyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-asparagyl-L-cysteinyl-L-prolyl-L-lysyl-glycinamide (4->9)-disulfide;terlypressin;triglycylvasopressin;TGLVP;914453-96-6;triglycyl lysine vasopressin;Terlipressin?;Terlipressin [USAN:INN:BAN];Lucassin (TN);HS-2028;Terlipressin (USAN/INN);SCHEMBL22699;TERLIPRESSIN (MART.);CHEMBL2135460;GTPL11241;H01BA04;BENFXAYNYRLAIU-QSVFAHTRSA-N;CHEBI:135905;TERLIPRESSIN (EP MONOGRAPH);EX-A3116;Tox21_113374;AKOS015994637;CCG-270662;CS-5769;DB02638;DA-58411;HY-12554;CAS-14636-12-5;NS00024791;C72780;D06672;GLYCYLGLYCYLGLYCYL(8-L-LYSINE)VASOPRESSIN;N-(N-(N-glycylglycyl)glycyl)-L-lysinevasopressin;Q324147;BRD-K73451719-001-01-2;VASOPRESSIN, N-(GLYCYLGLYCYLGLYCYL)-8-L-LYSINE-;GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE);(2S)-6-amino-2-{[(2S)-1-{[(4R,7S,10S,13S,16S,19R)-19-{2-[2-(2-aminoacetamido)acetamido]acetamido}-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)hexanamide;238-680-8;
Chemical Name: (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C52H74N16O15S2 |
M.W/Mr. | 1227.4 |
Sequence | One Letter Code:GGGCYFQNCPKG Three Letter Code:H-Gly-Gly-Gly-Cys(1)-Tyr-Phe-Gln-Asn-Cys(1)-Pro-Lys-Gly-NH2 |
Activity | Agonist |
Biological Activity | Terlipressin is an analogue of vasopressin used as a vasoactive drug in the management of hypotension which has been found to be effective when norepinephrine fails. |
Target | Vasopressin Receptor |
Long-term Storage Conditions | DMF: 20 mg/ml DMSO: 25 mg/ml Ethanol: Partially soluble PBS (pH 7.2): 10 mg/ml |
InChI | InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1 |
InChI Key | BENFXAYNYRLAIU-QSVFAHTRSA-N |
Canonical SMILES | C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N |
Isomeric SMILES | C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N |
3. Emu oil in combination with other active ingredients for treating skin imperfections
4. Myotropic activity of allatostatins in tenebrionid beetles
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.